Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free IMNM Stock Alerts

Immunome (IMNM) Financials

Immunome logo
$18.22 -0.17 (-0.91%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Immunome

Annual Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -10 -18 -25 -38 -107 -293 -212
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293 -212
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293 -212
Total Pre-Tax Income 		-10 -18 -25 -37 -107 -293 -212
Total Operating Income		 -10 -12 -25 -37 -110 -306 -224
Total Gross Profit		 0.00 0.00 0.00 0.00 14 9.04 6.94
Total Revenue		 0.00 0.00 0.00 0.00 14 9.04 6.94
Operating Revenue		 - - - 0.00 14 9.04 6.94
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 12 25 37 124 315 231
Selling, General & Admin Expense		 1.53 4.78 11 14 20 33 44
Research & Development Expense		 8.82 7.49 14 23 104 282 187
Total Other Income / (Expense), net		 -0.10 -5.58 0.49 0.01 2.72 13 12
Interest Expense		 0.10 0.04 0.01 -0.01 -2.72 -13 -12
Basic Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Weighted Average Basic Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M 87.35M
Diluted Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Weighted Average Diluted Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M 87.35M
Weighted Average Basic & Diluted Shares Outstanding		 1.09M 3.39M 12.13M 12.22M 59.69M 86.95M 113.13M

Quarterly Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Consolidated Net Income / (Loss)		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Net Income / (Loss) Continuing Operations		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Total Pre-Tax Income 		-4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Total Operating Income		 -4.63 -95 -132 -40 -51 -83 -45 -46 -60 -73 -59
Total Gross Profit		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Total Revenue		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Operating Revenue		 3.57 3.83 1.03 2.36 2.91 2.74 2.93 4.02 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.20 98 133 42 53 86 48 50 60 73 59
Selling, General & Admin Expense		 4.38 8.04 6.01 6.98 9.53 10 11 10 11 12 13
Research & Development Expense		 3.82 90 127 35 44 75 37 40 49 61 46
Total Other Income / (Expense), net		 0.29 2.02 2.81 3.89 3.42 2.72 3.00 3.08 2.68 2.96 5.49
Interest Expense		 -0.29 -2.02 -2.81 -3.89 -3.42 -2.72 -3.00 -3.08 -2.68 -2.96 -5.49
Basic Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Weighted Average Basic Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Diluted Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Weighted Average Diluted Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Weighted Average Basic & Diluted Shares Outstanding		 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M 87.05M 91.71M 113.13M 113.25M

Annual Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.94 37 9.46 -29 78 45 510
Net Cash From Operating Activities		 -9.60 -12 -18 -29 -7.57 -111 -191
Net Cash From Continuing Operating Activities		 -9.60 -12 -18 -29 -7.57 -111 -191
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293 -212
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293 -212
Depreciation Expense		 0.62 0.76 0.76 0.42 0.46 1.57 2.47
Amortization Expense		 - - 0.00 0.21 -0.24 -2.36 -2.35
Non-Cash Adjustments To Reconcile Net Income		 0.02 6.16 2.95 5.33 87 168 37
Changes in Operating Assets and Liabilities, net		 0.21 -1.21 2.78 2.24 12 15 -15
Net Cash From Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85 61
Net Cash From Continuing Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85 61
Purchase of Property, Plant & Equipment		 -0.23 -0.59 -0.08 -0.25 -0.83 -7.17 -9.69
Acquisitions		 - - - - 0.00 -46 -6.25
Purchase of Investments		 - - - 0.00 -39 -187 -123
Divestitures		 - - - 0.00 9.28 0.00 0.00
Sale and/or Maturity of Investments		 - - - - 0.00 155 200
Net Cash From Financing Activities		 11 50 28 0.03 116 241 640
Net Cash From Continuing Financing Activities		 11 50 28 0.03 116 241 640
Issuance of Common Equity		 0.00 39 29 0.00 125 20 46
Other Financing Activities, net		 -0.22 -0.19 -0.80 0.03 -8.63 221 594

Quarterly Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 52 8.04 171 -104 -9.76 -12 114 -114 129 381 -71
Net Cash From Operating Activities		 -8.61 -17 -11 -23 -34 -42 -53 -49 -41 -48 -59
Net Cash From Continuing Operating Activities		 -8.61 -17 -11 -23 -34 -42 -53 -49 -41 -48 -59
Net Income / (Loss) Continuing Operations		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Consolidated Net Income / (Loss)		 -4.35 -93 -129 -36 -47 -80 -42 -43 -57 -70 -54
Depreciation Expense		 0.11 0.15 0.16 0.55 0.41 0.45 0.61 0.64 0.59 0.63 0.60
Amortization Expense		 0.39 -0.74 -0.43 -0.23 -1.31 -0.39 -0.70 -1.12 -0.67 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income		 1.09 84 114 9.50 12 33 5.64 6.42 6.57 18 7.87
Changes in Operating Assets and Liabilities, net		 -5.85 -8.14 4.51 2.91 2.31 5.21 -17 -12 10 3.22 -13
Net Cash From Investing Activities		 -0.04 -30 -37 -82 24 9.76 5.09 -64 124 -4.00 -12
Net Cash From Continuing Investing Activities		 -0.04 -30 -37 -82 24 9.76 5.09 -64 124 -4.00 -12
Purchase of Property, Plant & Equipment		 -0.04 -0.35 -2.16 -2.34 -1.54 -1.13 -3.67 -0.91 -1.12 -4.00 -3.00
Acquisitions		 - - -35 -6.66 -4.36 -0.25 -6.25 - - - -9.01
Sale and/or Maturity of Investments		 - - 0.00 - 30 85 15 60 125 - 0.00
Net Cash From Financing Activities		 61 55 219 0.69 0.31 20 162 -0.06 45 433 -0.14
Net Cash From Continuing Financing Activities		 61 55 219 0.69 0.31 20 162 -0.06 45 433 -0.14
Issuance of Debt		 - - 230 - - - 173 - - - 0.00
Issuance of Common Equity		 61 64 - - - 20 0.00 - - - 0.00
Other Financing Activities, net		 -0.13 -8.50 -11 0.69 0.31 0.09 -10 -0.06 -0.51 605 -0.14

Annual Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5.06 45 58 24 149 240 683
Total Current Assets		 3.12 43 57 23 145 221 661
Cash & Equivalents		 2.54 40 49 20 99 143 653
Short-Term Investments		 - - - 0.00 39 74 0.00
Prepaid Expenses		 0.58 3.13 7.41 2.33 6.56 4.04 7.30
Plant, Property, & Equipment, net		 1.70 1.53 0.86 0.68 2.07 10 15
Total Noncurrent Assets		 0.24 0.10 0.43 0.72 1.76 8.79 7.78
Other Noncurrent Operating Assets		 0.24 0.10 0.43 0.72 1.76 8.79 7.78
Total Liabilities & Shareholders' Equity		 5.06 45 58 24 149 240 683
Total Liabilities		 1.80 3.18 9.74 7.39 29 59 49
Total Current Liabilities		 1.67 3.04 9.73 7.33 22 54 45
Accounts Payable		 0.55 1.19 3.08 2.40 3.31 14 3.34
Accrued Expenses		 0.67 1.37 6.65 4.93 8.03 33 42
Current Deferred Revenue		 - - - 0.00 10 6.94 0.00
Total Noncurrent Liabilities		 0.13 0.14 0.01 0.06 6.83 4.77 3.86
Other Noncurrent Operating Liabilities		 0.11 - 0.01 0.06 1.34 4.77 3.86
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -36 41 48 17 120 181 634
Total Preferred & Common Equity		 -36 41 48 17 120 181 634
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -36 41 48 17 120 181 634
Common Stock		 0.93 96 127 133 343 697 1,363
Retained Earnings		 -37 -54 -79 -116 -223 -516 -728
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.02 0.06 0.00

Quarterly Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 31 48 41 93 320 296 257 343 296 299 620
Total Current Assets		 29 47 40 91 313 284 244 323 277 280 594
Cash & Equivalents		 27 44 38 91 270 165 156 258 144 273 583
Short-Term Investments		 - - - - 40 113 85 60 124 0.00 0.00
Prepaid Expenses		 2.16 2.11 1.11 0.77 3.62 5.93 3.91 5.81 9.40 7.29 12
Plant, Property, & Equipment, net		 0.70 0.92 1.20 1.17 4.30 6.10 7.17 11 11 12 17
Total Noncurrent Assets		 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61 7.83 7.89 8.40
Other Noncurrent Operating Assets		 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61 7.83 7.89 8.40
Total Liabilities & Shareholders' Equity		 31 48 41 93 320 296 257 343 296 299 620
Total Liabilities		 7.46 34 32 87 34 42 42 36 27 35 31
Total Current Liabilities		 7.37 25 26 23 31 40 40 31 23 31 27
Accounts Payable		 3.14 3.31 3.70 2.79 7.18 7.05 3.52 9.13 4.66 6.15 5.53
Accrued Expenses		 4.23 3.31 5.03 3.37 11 20 26 18 18 25 22
Current Deferred Revenue		 - 18 18 17 13 13 9.68 4.02 0.00 0.00 0.00
Total Noncurrent Liabilities		 0.09 9.42 5.71 64 3.41 2.48 2.46 4.77 4.14 4.01 3.69
Other Noncurrent Operating Liabilities		 0.09 0.00 0.00 61 1.21 2.48 2.46 4.77 4.14 4.01 3.69
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 14 9.34 6.08 286 254 215 307 269 264 589
Total Preferred & Common Equity		 23 14 9.34 6.08 286 254 215 307 269 264 589
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 23 14 9.34 6.08 286 254 215 307 269 264 589
Common Stock		 131 134 135 136 638 642 650 865 870 922 1,371
Retained Earnings		 -108 -120 -126 -130 -352 -388 -436 -557 -601 -658 -782
Accumulated Other Comprehensive Income / (Loss)		 - - - - 0.00 0.00 0.07 -0.00 -0.02 0.00 0.00

Annual Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 91,710,277.00
DEI Adjusted Shares Outstanding		 - - - - - - 91,710,277.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -2.32
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214 -157
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -63.96% -118.16% -24.73%
Earnings before Interest and Taxes (EBIT)		 -10 -18 -25 -37 -110 -306 -224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.73 -17 -24 -36 -109 -307 -224
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.94 -15 -23 -62 -196 -174
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.72 2.08 -1.04 -3.67 -18 -36 -19
Increase / (Decrease) in Invested Capital		 0.00 1.36 -3.12 -2.63 -15 -18 17
Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90 $6.92
Tangible Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90 $6.92
Total Capital		 3.26 42 48 17 120 181 634
Total Debt		 0.00 0.50 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.13 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.54 -39 -49 -20 -138 -217 -653
Capital Expenditures (CapEx)		 0.23 0.59 0.08 0.25 0.83 7.17 9.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.09 0.46 -2.32 -5.01 -15 -50 -38
Debt-free Net Working Capital (DFNWC)		 1.46 40 47 15 123 167 616
Net Working Capital (NWC)		 1.46 40 47 15 123 167 616
Net Nonoperating Expense (NNE)		 3.20 9.25 7.07 11 30 79 56
Net Nonoperating Obligations (NNO)		 -2.54 -39 -49 -20 -138 -217 -653
Total Depreciation and Amortization (D&A)		 0.62 0.76 0.76 0.63 0.22 -0.80 0.12
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M 87.35M
Adjusted Diluted Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00) ($2.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M 87.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.26) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.39M 12.13M 12.22M 59.69M 86.95M 113.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214 -157
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 91,710,277.00 113,133,199.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 91,710,277.00 113,133,199.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.76 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -56.47% -44.55% -18.37% -28.44% 184.35% 69.84% -100.00% - -100.00%
EBITDA Growth		 50.89% -1,165.31% -2,966.71% -606.70% -1,143.63% 12.95% 66.26% -18.33% -17.11% - -30.96%
EBIT Growth		 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26% -16.17% -19.03% - -32.92%
NOPAT Growth		 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26% -16.17% -19.03% - -32.92%
Net Income Growth		 49.08% -1,089.75% -2,932.60% -550.03% -984.00% 13.37% 67.84% -20.14% -21.99% - -29.30%
EPS Growth		 52.00% -557.81% -617.14% -30.43% -116.67% 73.63% 79.28% 16.67% 16.67% - 7.69%
Operating Cash Flow Growth		 -13.78% -161.24% -146.21% -312.79% -296.65% -140.91% -374.98% -111.14% -18.56% - -10.52%
Free Cash Flow Firm Growth		 2,354.59% -1,728.99% -541.59% -257.61% -222.47% 22.19% 54.38% -78.95% 38.12% - -27.75%
Invested Capital Growth		 -2,017.30% -397.55% 21.03% 15.69% 70.17% -97.91% 57.75% 105.03% 65.43% - 158.77%
Revenue Q/Q Growth		 -16.37% 7.32% -73.11% 129.74% 23.10% -5.91% 6.87% 37.22% -100.00% - 0.00%
EBITDA Q/Q Growth		 26.37% -2,203.26% -39.69% 70.06% -29.57% -61.23% 46.05% -5.00% -28.23% - 18.74%
EBIT Q/Q Growth		 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20% -4.13% -29.39% - 18.57%
NOPAT Q/Q Growth		 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20% -4.13% -29.39% - 18.57%
Net Income Q/Q Growth		 21.81% -2,031.97% -39.79% 72.10% -30.39% -70.38% 48.11% -4.22% -32.40% - 22.98%
EPS Q/Q Growth		 21.74% -1,069.44% 40.38% 76.10% -30.00% -42.31% 53.15% 3.85% -30.00% - 36.84%
Operating Cash Flow Q/Q Growth		 -51.98% -102.68% 36.02% -109.46% -46.03% -23.10% -26.14% 6.89% 18.00% - -22.28%
Free Cash Flow Firm Q/Q Growth		 274.20% -166.82% -91.68% 67.11% -190.78% 57.55% -12.39% -29.00% -0.54% - 15.12%
Invested Capital Q/Q Growth		 -190.82% 78.41% -32.17% -1.58% -2.89% -43.27% 71.78% 112.10% -806.65% - 131.31%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% - 0.00%
EBITDA Margin		 -115.99% -2,489.28% -12,883.77% -1,678.85% -1,767.15% -3,028.16% -1,528.64% -1,169.69% 0.00% - 0.00%
Operating Margin		 -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50% -1,157.61% 0.00% - 0.00%
EBIT Margin		 -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50% -1,157.61% 0.00% - 0.00%
Profit (Net Income) Margin		 -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10% -1,080.87% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 93.78% 97.87% 97.88% 90.28% 93.23% 96.72% 93.29% 93.37% 95.54% - 90.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21% -81.20% -93.04% - -50.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,827.65% 0.00% - -3,059.50%
Operating Return on Assets (OROA)		 -21.41% -401.88% -886.55% -108.11% -100.47% -140.94% -50.38% -49.19% 0.00% - 0.00%
Return on Assets (ROA)		 -20.08% -393.31% -867.74% -97.60% -93.67% -136.32% -47.00% -45.93% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21% -81.20% -93.04% - -50.14%
Return on Equity Simple (ROE_SIMPLE)		 -361.39% 0.00% -81.25% -103.45% -142.08% 0.00% -66.78% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.24 -66 -93 -28 -35 -58 -31 -33 -42 -51 -42
NOPAT Margin		 -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85% -810.33% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.87% -33.29% -20.83% -5.12% -7.10% -12.47% -3.32% -3.98% -5.99% - -2.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -55.27% - - - -32.06% -10.17% -12.08% -15.95% -8.04% -7.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 122.72% 210.14% 583.58% 295.18% 327.35% 381.52% 365.35% 250.11% 0.00% - 0.00%
R&D to Revenue		 107.24% 2,363.80% 12,373.47% 1,497.25% 1,508.80% 2,748.79% 1,260.15% 1,007.50% 0.00% - 0.00%
Operating Expenses to Revenue		 229.96% 2,573.94% 12,957.05% 1,792.43% 1,836.15% 3,130.31% 1,625.50% 1,257.61% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.63 -95 -132 -40 -51 -83 -45 -46 -60 -73 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.14 -95 -133 -40 -51 -83 -45 -47 -60 -72 -59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.77 3.81 5.16 2.86 4.09 3.66 1.91 3.01 3.86 - 4.20
Price to Tangible Book Value (P/TBV)		 16.77 3.81 5.16 2.86 4.09 3.66 1.91 3.01 3.86 - 4.20
Price to Revenue (P/Rev)		 10.00 32.62 116.16 67.29 86.68 73.32 53.50 64.28 105.31 - 616.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 438.56 0.00 - 315.62
Enterprise Value to Revenue (EV/Rev)		 1.10 22.76 91.74 41.48 62.97 49.28 24.49 42.99 77.14 - 471.12
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 3.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -4.04 -1.16 -1.18 -1.20 -1.50 -1.18 -1.06 -1.04 -1.07 - -1.00
Leverage Ratio		 4.24 1.26 1.23 1.28 1.58 1.29 1.12 1.13 1.16 - 1.07
Compound Leverage Factor		 3.98 1.24 1.20 1.16 1.48 1.25 1.04 1.06 1.11 - 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -0.43 6.46 24.05 9.02 10.52 3.46 8.22 15.69 14.54 - 46.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.96 6.63 10.18 7.12 6.17 4.08 10.49 12.13 8.90 - 21.68
Quick Ratio		 3.92 6.33 10.07 6.98 6.07 4.00 10.30 11.72 8.67 - 21.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 77 -52 -99 -33 -95 -40 -45 -58 -59 -68 -58
Operating Cash Flow to CapEx		 -23,927.78% -5,002.58% -516.17% -998.17% -2,220.08% -3,735.35% -1,447.61% -5,458.67% -3,629.93% - -1,953.30%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.16 0.07 0.06 0.06 0.05 0.03 0.04 0.03 - 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 10.87 10.18 4.86 2.95 2.43 1.48 1.43 1.47 1.03 - 0.29
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -85 -18 -24 -25 -25 -36 -10 1.23 -8.72 -19 5.99
Invested Capital Turnover		 -0.23 -1.28 -0.46 -0.40 -0.18 -0.33 -0.64 -1.08 -0.57 - -1.91
Increase / (Decrease) in Invested Capital		 -81 -15 6.43 4.56 59 -18 14 26 17 17 16
Enterprise Value (EV)		 11 319 1,164 447 638 446 268 541 747 - 1,892
Market Capitalization		 102 457 1,473 726 878 663 585 809 1,019 - 2,474
Book Value per Share		 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53 $3.09 $3.03 $6.92 $5.20
Tangible Book Value per Share		 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53 $3.09 $3.03 $6.92 $5.20
Total Capital		 6.08 120 286 254 215 181 307 269 264 634 589
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -91 -138 -310 -278 -240 -217 -317 -268 -273 -653 -583
Capital Expenditures (CapEx)		 0.04 0.35 2.16 2.34 1.54 1.13 3.67 0.91 1.12 4.00 3.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -15 -27 -34 -36 -50 -25 -13 -24 -38 -16
Debt-free Net Working Capital (DFNWC)		 68 123 283 244 205 167 292 255 248 616 567
Net Working Capital (NWC)		 68 123 283 244 205 167 292 255 248 616 567
Net Nonoperating Expense (NNE)		 1.10 26 37 8.12 12 22 10 11 15 19 12
Net Nonoperating Obligations (NNO)		 -91 -138 -310 -278 -240 -217 -317 -268 -273 -653 -583
Total Depreciation and Amortization (D&A)		 0.50 -0.59 -0.28 0.32 -0.90 0.06 -0.09 -0.49 -0.08 0.78 0.75
Debt-free, Cash-free Net Working Capital to Revenue		 -219.17% -108.92% -214.05% -314.99% -351.64% -556.03% -228.47% -107.09% -249.61% - -393.42%
Debt-free Net Working Capital to Revenue		 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64% 2,022.04% 2,567.20% - 14,119.48%
Net Working Capital to Revenue		 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64% 2,022.04% 2,567.20% - 14,119.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Adjusted Diluted Earnings per Share		 ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52) ($0.50) ($0.65) ($0.76) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M 87.01M 87.96M 87.35M 113.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M 87.05M 91.71M 113.13M 113.25M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.24 -66 -93 -28 -35 -58 -31 -33 -42 -51 -42
Normalized NOPAT Margin		 -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85% -810.33% 0.00% - 0.00%
Pre Tax Income Margin		 -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10% -1,080.87% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Immunome’s latest quarter shows a company with a very large cash cushion, but also significant operating losses as it continues to invest heavily in research and development. In Q1 2026, the company reported no revenue, a net loss of $53.8 million, and negative operating cash flow of $58.6 million. That said, Immunome ended the quarter with $582.7 million in cash and equivalents, which gives it considerable financial flexibility.

  • Large cash position: Cash and equivalents rose to $582.7 million at March 31, 2026, up from $272.6 million at the end of Q3 2025 and $143.9 million at the end of Q2 2025.
  • Balance sheet remains strong: Total current assets of $594.3 million comfortably exceed total liabilities of $31.1 million, supporting near-term liquidity.
  • Debt is very low in the latest quarter: The Q1 2026 balance sheet shows no new debt issuance in the quarter, and financing cash outflow was only $135,000.
  • Operating expenses improved sequentially: Q1 2026 operating expenses were $59.3 million, down from $72.9 million in Q4 2025.
  • Net loss narrowed versus the prior quarter: Losses improved to $53.8 million from $69.9 million in Q4 2025.
  • No product revenue yet: Q1 2026 reported revenue remained at $0, so the company is still dependent on capital reserves and external funding rather than commercial sales.
  • Heavy R&D spending continues: Research and development expense was $46.4 million in Q1 2026, consistent with a development-stage biotech model focused on pipeline progress.
  • Interest expense is meaningful: Interest expense was $5.5 million in Q1 2026, which is sizable relative to the company’s current lack of revenue.
  • Share count was stable quarter to quarter: Weighted average diluted shares were 113.1 million in Q1 2026, little changed from Q4 2025.
  • Operating cash burn remains high: Immunome used $58.6 million in operating cash in Q1 2026, after using $47.9 million in Q4 2025.
  • Quarterly losses remain substantial: The company has now posted several consecutive large quarterly losses, including $53.8 million in Q1 2026 and $69.9 million in Q4 2025.
  • Cash declined from the prior quarter’s peak: Although still very strong, cash fell from $582.7 million in Q1 2026 versus the prior quarter’s higher cash levels after investment activity and operating outflows.
  • Acquisition spending continues: Q1 2026 included $9.0 million of acquisition-related cash outflows, adding to the company’s overall spending profile.

Looking at the broader trend over the last four years, Immunome has transformed from a very small, cash-light biotech into a much better-funded company. Cash and investments have expanded dramatically since 2023, helped by financing and investing activity, but the core business still generates no revenue and remains loss-making. That means the key investment question is whether management can convert this balance-sheet strength into clinical and commercial value before cash burn becomes a concern.

Bottom line: Immunome’s financial position is much stronger than it was a year ago, and the company appears well-capitalized for now. However, investors should still view it as a high-risk biotech story: strong liquidity on one side, but persistent losses, no sales, and ongoing cash burn on the other.

06/10/26 11:02 AM ETAI Generated. May Contain Errors.

Immunome Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immunome's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Immunome's net income appears to be on an upward trend, with a most recent value of -$212.39 million in 2025, rising from -$10.44 million in 2019. The previous period was -$292.96 million in 2024. Check out Immunome's forecast to explore projected trends and price targets.

Immunome's total operating income in 2025 was -$224.11 million, based on the following breakdown:
  • Total Gross Profit: $6.94 million
  • Total Operating Expenses: $231.05 million

Over the last 6 years, Immunome's total revenue changed from $0.00 in 2019 to $6.94 million in 2025, a change of 694,100,000.0%.

Immunome's total liabilities were at $48.85 million at the end of 2025, a 17.3% decrease from 2024, and a 2,619.7% increase since 2019.

In the past 6 years, Immunome's cash and equivalents has ranged from $2.54 million in 2019 to $653.48 million in 2025, and is currently $653.48 million as of their latest financial filing in 2025.

Over the last 6 years, Immunome's book value per share changed from -32.57 in 2019 to 6.92 in 2025, a change of -121.2%.


Related Companies

Financial statements for NASDAQ:IMNM last updated on 5/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
$3 Trillion AI Power Crunch Creating a New Market
Microsoft, Amazon, Alphabet, and Meta are projected to invest $650 billion in data centers this year alone - a...
i2i Marketing Group, LLC | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Free: The Crypto Summit That Could Change Your Life
27 of the top crypto experts in the world… multi-millionaires, fund managers, coin creators, underground trade...
Crypto 101 Media | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
Tesla. SolarCity. Twitter. This $4 stock is next.
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...
Behind the Markets | Sponsoredtc pixel